Summary: Molybdenum hydroxylases, which include aldehyde oxidase and xanthine oxidoreductase, are involved in the metabolism of some medicines in humans. They exhibit oxidase activity towards various heterocyclic compounds and aldehydes. The liver cytosol of various mammals also exhibits a signiˆcant reductase activity toward nitro, sulfoxide, N-oxide and other moieties, catalyzed by aldehyde oxidase. There is considerable variability of aldehyde oxidase activity in liver cytosol of mammals: humans show the highest activity, rats and mice show low activity, and dogs have no detectable activity. On the other hand, xanthine oxidoreductase activity is present widely among species. Interindividual variation of aldehyde oxidase activity is present in humans. Drug-drug interactions associated with aldehyde oxidase and xanthine oxidoreductase are of potential clinical signiˆcance. Drug metabolizing ability of molybdenum hydroxylases and the variation of the activity are described in this review.
Introduction
Molybdenum hydroxylases, which include aldehyde oxidase (EC 1.2.3.1) and xanthine oxidase (EC 1.17.3.2) W xanthine dehydrogenase (EC 1.17.1.4), commonly contain FAD, molybdenum and an ironsulfur center in the active site. The properties of these enzymes are closely related. [1] [2] [3] In mammals, xanthine oxidoreductase exists in two interconvertible forms, xanthine dehydrogenase, which predominates in vivo, and xanthine oxidase. In this review, xanthine oxidoreductase is taken to be the total of xanthine oxidase and xanthine dehydrogenase. Aldehyde oxidase and xanthine oxidoreductase commonly exist in vertebrates. 4) These cytosolic enzymes have a very close evolutionary relationship (based on the recent cloning of the genes), and they show a high degree of amino acid sequence homology. [5] [6] [7] [8] The physiological function of aldehyde oxidase is not yet fully understood. The ‰avoenzyme may merely play a supplementary role to aldehyde dehydrogenase. However, aldehyde oxidase has been suggested to be relevant to the pathophysiology of a number of clinical disorders. 9) Its relevance to amyotrophic lateral sclerosis is suggested by the hypothesis that defects in oxygen radical metabolism by the enzyme may be involved in the pathogenesis of this disease. 10, 11) Aldehyde oxidase may also play a major role in the pathogenesis of alcohol-induced liver injury, while xanthine oxidoreductase plays a minor role. 9) Aldehyde oxidase and xanthine oxidoreductase both play important roles in the metabolism of exogenous compounds. These ‰avoenzymes generally catalyze nucleophilic oxidation of N-heterocycles, resulting in diŠerent metabolites from those obtained via electrophilic oxidation by the cytochrome P450 system. However, the substrate speciˆcities of aldehyde oxidase and xanthine oxidoreductase diŠer. 12) Aldehyde oxidase in liver of various species catalyzes the oxidation of a number of aldehydes and nitrogenous heterocyclic xenobiotics, such as methotrexate and cyclophosphamide, 1, 13) and also catalyzes the metabolism of physiological compounds such as retinaldehyde, pyridoxal, N 1 -methylnicotinamide and monoamine neurotransmitters. [14] [15] [16] [17] The conventionally accepted role of xanthine oxidoreductase is purine catabolism, in which it catalyzes the oxidation of hypoxanthine to xanthine, then to uric acid. The two enzymes, in the presence of an adequate electron donor, can also mediate the reduction of various other compounds. 18) Recently, aldehyde oxidase homologues, which may have diŠerent metabolic roles, were identiˆed in mice, 8, 19, 20) and isoforms of the enzyme were also suggested to be present in monkeys and humans. 21, 22) Marked inter-species variation of the enzyme activity in oxidative and reductive reactions was reported. 23, 24) This review focuses on the metabolic ability of molybdenum hydroxylases toward medicines, as well as the role of these enzymes in drug-drug interactions, and interindividual diŠerences in their activities.
Characterization of Molybdenum Hydroxylases
Xanthine oxidoreductase and aldehyde oxidase are complex ‰avoproteins comprising two identical subunits of molecular weight 145,000. Each subunit contains one molybdenum, one FAD, and two nonidentical ironsulfur redox centers as an electron reservoir.
13) The optimal pH of these enzymes is estimated to be 9-10.
5.25,26) Garattini et al. 20) demonstrated that subunits of xanthine oxidoreductase have a tripartite structure, consisting of the 2Fe W 2S N-terminal domain (20 kDa), ‰avin-containing region (40 kDa), and Mo-containing C-terminal domain (substrate binding site; 85 kDa). Branzoli and Massey 27) showed that de‰avo aldehyde oxidase can reduce cytochrome c, but cannot transfer electrons to oxygen. It is presumed that electron donors such as xanthine act at the molybdenum site, reducing it from Mo(VI) to the Mo(IV) state. The reducing equivalents transfer directly to the FAD site or via the iron-sulfur center, and the enzyme is reoxidized by interaction with oxygen.
28) Then, an oxygen atom from water binds with the electron donor which lost electron. In this case, the iron-sulfur center functions not only as the pathway of electron ‰ow, but also as an electron sink to provide electrons to the FAD center.
29) The proposed internal electron transport system is summarized in Fig. 1 .
Xanthine dehydrogenase is easily converted to xanthine oxidase by proteolysis.
30) Both forms of the enzyme can reduce molecular oxygen, although xanthine dehydrogenase can reduce NAD, which is its preferred electron acceptor. Reduction of oxygen leads to the formation of superoxide anion and hydrogen peroxide. This capacity has attracted attention to the possible role of xanthine oxidoreductase as a source of reactive oxygen species, particularly as a pathogenic agent in many forms of ischemia-reperfusion injury.
31)
The role of the enzyme in post-ischemic reperfusion tissue injury has been widely investigated.
32) However, xanthine oxidoreductase may also play beneˆcial roles. Tubaro et al. 33) suggested that superoxide radical produced by xanthine oxidoreductase acts as an antimicrobial agent. It was also proposed that uric acid produced by xanthine oxidoreductase forms a part of the protective system against oxygen radicals.
34,35)
Aldehyde oxidase and xanthine oxidoreductase have been puriˆed from many species. Aldehyde oxidase has been puriˆed from livers of rat, 36,37) mouse, 38) guinea pig, 39) rabbit, 26, 27, 40, 41) hog, 26) monkey 22) and hamster. 42) Aldehyde oxidase was also puriˆed fromˆsh liver. 43) This enzyme functions as a reductase toward nitropolycyclic aromatic hydrocarbons and sulfoxide compounds inˆsh. [43] [44] [45] Xanthine oxidoreductase has been puriˆed from the livers of various species and from milk, and its properties were compared with those of aldehyde oxidase. 2, 37, 46, 47) 
Species and Tissue DiŠerences of Molybdenum Hydroxylases
Molybdenum hydroxylases are found in many species, includingˆsh and insect. 4, 43, 48, 49) However, there are marked species and strain diŠerences (in rats and mice) and sex diŠerence (in mice) of liver aldehyde oxidase. 4, [50] [51] [52] [53] [54] Broadly speaking, high activity is observed in monkey and humans, followed by hamster, rabbit, guinea pig, rat and mouse, and no activity in dog. 17, 55) Aldehyde oxidase is also found inˆsh and insects, but not in birds. 48) Beedham et al. 56) suggested that the marked species diŠerences of aldehyde oxidase activity toward 1-substituted phthalazines are due to diŠerences in the size of the active site. It was also shown that the substrate speciˆcities of the hepatic enzyme from guinea pig, rabbit, baboon and human for substituted quinazolines and phthalazines are due to the lipophilic substituents, and the species diŠerences are due to the size of the binding site. 57) Schoˆeld et al. 24) reported that guinea pig and rat aldehyde oxidase preparations are not suitable for predicting aldehyde oxidase-mediated drug-drug interactions in humans, because of diŠerences in the inhibitory activity of SKF 525-A on aldehyde oxidase activity towards N-[(2?-dimethylamino)ethyl]acridine-4-carboxamide (an an-ticancer agent) as a substrate among liver preparations from humans, and rats and guinea pigs. Molybdenum hydroxylases have been shown to be distributed in many tissues. 4) Xanthine oxidoreductase is detected in liver, small intestine, forestomach, vagina, penis, oral and nasal cavities, esophagus, tongue and uterus. 9) Immunohistochemical analysis also conˆrmed that xanthine oxidoreductase is distributed in epidermis, sebaceous glands and hair follicle epithelium in rats, while aldehyde oxidase is also similarly distributed, except in epidermis. 9, 58) Moreover, in mice, mRNA of aldehyde oxidase was detected in esophagus, lung, liver and testis, but not skin. 59) Tereo et al. 7) cloned cDNA for AOH1 and AOH2, novel aldehyde oxidase analogues, and demonstrated that mRNA of AOH2 is present in the basal layer of the epidermis and hair follicles in mice.
Recently, we detected aldehyde oxidase and xanthine oxidoreductase activities in skin of various mammals, and found clear species diŠerences in the levels of their activities. The aldehyde oxidase and xanthine oxidoreductase activities in skin of various species appeared to be complementary, i.e., when one was high, the other was low. In addition, the pattern of species diŠerence of these enzymes in skin cytosol was similar to that in liver. 60, 61) However, the physiological roles of these enzymes in skin are still unknown. Possible roles include homeostatic control of vitamins, such as retinoids, and other biologically active molecules, and elimination of biogenic wastes or breakdown products generated by ultraviolet radiation and other environmental stresses. 20, 62) Aldehyde oxidase in bovine eye ciliary body was puriˆed and characterized. 63) However, the physiological role of the enzyme in ciliary body is also not known. As regards subcellular distribution, xanthine oxidoreductase and aldehyde oxidase are mainly distributed in the cytosol fraction of tissues. Critchley et al. 64) reported that xanthine oxidoreductase and aldehyde oxidase are localized in mitochondrial fraction of guinea pig liver. However, we could notˆnd the activity of either of these ‰avoenzymes in liver mitochondrial fraction of guinea pigs.
Oxidative Drug-Metabolism by Molybdenum Hydroxylases
Aldehyde oxidase and xanthine oxidoreductase are known to promote nucleophilic attack at an electrondeˆcient carbon atom adjacent to a ring nitrogen atom, e.g., in pyridine, pyrazine, purine, pyrimidine, quinoline and pteridine, although the attack does not necessarily occur at a single site in N-containing heterocycles. 12) Hall and Krenitsky 65) demonstrated that the electron-withdrawing character of 6-substituents of purine and their hydrophobicity are important factors determining aldehyde oxidase activity toward purines and their analogs. In general, aldehyde oxidase has the ability to oxidize a wide variety of substrates, compared with xanthine oxidoreductase.
Some anticancer agents are metabolized by aldehyde oxidase, as shown in Fig. 2 . Methotrexate is oxidized to 7-hydroxymethotrexate by aldehyde oxidase in the livers of rats, guinea pigs, rabbits and humans. 53, [66] [67] [68] Conversion of acridine carboxamide, an antitumor agent, to an acridone derivative is mediated by aldehyde oxidase.
69)
N-[(2?-Dimethylamino)ethyl]acridine-4-carboxamide is also metabolized to the 9(10H)-acridone by aldehyde oxidase in rats, mice, guinea pigs and humans. 24, 54) An anticancer drug, XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]propionic acid, is metabolized to the oxo derivative by aldehyde oxidase. 70) Cinchona antimalarial alkaloids, quinine, quinidine, cinchonine, cinchonidine, epiquinidine and epiquinine, are oxidized by aldehyde oxidase, as shown in Fig. 2 .
71)
Itoh et al. 72, 73) also reported the aldehyde oxidasecatalyzed stereospeciˆc oxidation of a quinine-related compound, RS-8359, which is a potent inhibitor of MAO-A. Brimonidine, an ocular hypotensive agent, is activated by aldehyde oxidase. 74) Kawashima et al. 75) reported aldehyde oxidase-dependent metabolism of a sedative-hypnotic, zaleplon, and noted a marked species diŠerence between monkey and rats. Dibenz[b, f ]-1,4-oxazepine (a potent sensory irritant), hydralazine (an antihypertensive agent), and metyrapone are also oxidized to the lactam metabolites by aldehyde oxidase. 13, 76) Acyclovir, which is highly active toward herpes virus, is detoxiˆed to 8-hydroxyacyclovir by aldehyde oxidase. 13, 77) Purines are also oxidized by aldehyde oxidase, and in this case, hydrophobicity and an electron-withdrawing 6-substituent are important factors determining the e‹cency of the reaction. 65) Some prodrugs for anticancer agents are also activated by aldehyde oxidase, as shown in Fig. 2 . 5-Fluoro-2-pyrimidinone and 5-ethynyl-2(1H)-pyrimidinone are activated by aldehyde oxidase to 5-‰uorouracil and 5-ethynyluracil, respectively. 78, 79) 5-Ethynyluracil activates the pharmacological action of 5-‰uorouracil by inactivating dihydropyrimidine dehydrogenase, a detoxiˆca-tion enzyme of 5-‰uorouracil. 78) Harrell et al. 80) showed that BRL 55792, BRL 55791 and BRL 55039, deoxyguanine analogues that are prodrugs of an antiviral agent, 9-(3-hydroxypropoxy)guanine, were activated by xanthine oxidoreductase in rats and by aldehyde oxidase in humans. Thioguanine is activated to 8-hydroxythioguanine by human aldehyde oxidase. 81) Oxidation of famciclovir and 6-deoxypenciclovir to penciclovir is mediated by aldehyde oxidase. 52) Clarke et al. 82) reported a role of aldehyde oxidase in the in vitro conversion of famciclovir to the active antiviral penciclovir in human liver.
Nicotine is metabolized to nicotine D 1?(5?) iminium ion by the cytochrome P450 system, and to cotinine by aldehyde oxidase. 83) Prolintane, an sympathomimetic amine which is used to stimulate appetite, is also oxidized to oxoprolintane by aldehyde oxidase, via an iminium ion intermediate formed by the cytochrome P450 system. 84) Azapetine, an antihypertensive agent, is also converted to a lactam metabolite by aldehyde oxidase after biotransformation to the iminium ion by cytochrome P450. 13) In contrast, nicotinamide and ethionamide are not oxidized by aldehyde oxidase. However, ethionamide, a tuberculostatic agent, isˆrst methylated, and then the N-methylated ethionamide cation, which undergoes nucleophilic attack more readily than ethionamide, is oxidized to the 2-pyridone by aldehyde oxidase. 13) Nicotinamide is also oxidized to 2-and 4-pyridones after N-methylation as described later (see: Individual Variation of Drug-Metabolizing Ability of Molybdenum Hydroxylases). ABT-418, a selective cholinergic channel activator, is similarly oxidized by aldehyde oxidase in livers of rats, dogs, cynomolgus monkeys and humans. 85) Furthermore, Taylor et al. 86) reported that quinolines are oxidized to 2-and 4-quinolones by aldehyde oxidase, but quinolinium cations after N-alkylation are more oxidizable than quinolines (Fig. 3) .
The oxidase activity of aldehyde oxidase towards aldehyde compounds is generally lower than toward nitrogen-containing heterocyclic compounds. The anticancer drug cyclophosphamide and its isomeric analogue, ifosphamide, are activated to 4-hydroxyl metabolites, in equilibrium with the ring-opened form aldophosphamides, by CYP2B6 and CYP3A4, respectively. 87) Aldophosphamides undergo chemical decomposition to yield mustard-type alkylating agents (phosphoramide mustard and ifosphoramide mustard). These aldophosphamides are metabolized to the inactive carboxyphosphamides by aldehyde oxidase. 88) Pyridoxal and vitamin A aldehyde are also suggested to be oxidized by aldehyde oxidase. 14, 89, 90) Tolbutamide aldehyde, which is formed from tolbutamide by the Oxidations in thisˆgure involve iminium ion or nitrogen cation formation in the reaction sequences. cytochrome P450 system and alcohol dehydrogenase, is oxidized to carboxytolbutamide, a major urinary metabolite of tolbutamide, 91) as shown in Fig. 4 . Xanthine oxidoreductase participates in metabolism of purines, such as caŠeine, hypoxanthine and xanthine. 92) 6-Deoxyacyclovir, a highly absorbed prodrug of acyclovir, is activated by xanthine oxidoreductase to acyclovir. 77, 93) 6-Mercaptopurine is oxidized by liver aldehyde oxidase of rabbits and humans and bovine milk xanthine oxidoreductase to 6-mercaptopurin-8-one and 6-thiouric acid, respectively. 12, 94) Famciclovir is also metabolized by human liver xanthine oxidoreductase. 95) Allopurinol, an antihyperuricemic agent, is oxidized to the active metabolite, oxypurinol, by xanthine oxidoreductase and aldehyde oxidase. 96) Azathioprine is oxidized to 8-hydroxyazathioprine by aldehyde oxidase, and further metabolized to thiouric acid by xanthine oxidoreductase. 97) An antituberculous agent, pyrazinamide, is converted to the 5-oxo metabolite by xanthine oxidoreductase and aldehyde oxidase. 96, 98) 5-Fluorouracil, an antineoplastic agent, is also oxidized by these two enzymes 13) (Fig. 5) .
Reductive Drug-Metabolism by Molybdenum Hydroxylases
Aldehyde oxidase and xanthine oxidoreductase, in the presence of an adequate electron donor, can mediate the reduction of aromatic nitro compounds, such as nitrobenzoic acid, 1-nitropyrene, 2-nitro‰uorene, 4-nitroquinoline N-oxide and nitrofurazone. [99] [100] [101] [102] In nitro reduction with xanthine oxidoreductase, the enzyme exhibited uniformly high activity toward nitrofuran derivatives. However, in the case of nitrobenzene derivatives, high reducing ability was observed when an electron-withdrawing group was substituted at the pposition of the nitrobenzene. On the contrary, when an electron-donating group was present at the p-position, the activity was low compared with that towards nitrobenzene. 103) These enzymes also show reductase activity toward some aminoazo compounds and nicotinamide N-oxide. Moreover, aldehyde oxidase can mediate the reduction of various compounds other than those mentioned above, as shown in Fig. 6 . Sulfoxide compounds such as sulindac (an anti-in‰ammatory agent), phenothiazine sulfoxide and diphenyl sulfoxide are reduced to the corresponding sulˆde compounds by aldehyde oxidase.
108)
N-Oxide reductase activity of aldehyde oxidase toward imipramine N-oxide, cyclobenzaprine N-oxide, nicotine N-oxide and brucine N-oxide has been reported. [109] [110] [111] N-Nitrosodiphenylamine is also reduced to 1,1-diphenylhydrazine by aldehyde oxidase. 112) Hydroxamic acids, such as benzohydroxamic acid, salicylhydroxamic acid, a tuberculostatic agent, anthranylhydroxamic acid, nicotinohydroxamic acid and N-hydroxy-2-acetylamino‰uorene are reduced to the corresponding amides by aldehyde oxidase. 113, 114) Aldehyde oxidase also exhibits reductase activity toward azo compounds, such as p-dimethylaminoazobenzene, amaranth, methyl red and methyl orange, which are not reduced by xanthine oxidoreductase. 106, 115) The ‰avo enzyme also shows epoxide reductase activity toward benzo[a]pyrene 4,5-oxide and naphthalene 1,2-oxide. 116) The azide group of 3?-azido-3?-deoxythymidine (AZT), which is used for the treatment of the acquired immune deˆciency syndrome (AIDS), is reduced to an amino group by aldehyde oxidase, a reaction which is similar to that with the cytochrome P450 system. [117] [118] [119] The 1,2-benzisoxazole ring of zonisamide, an anticonvulsant agent, is reductively cleaved to the ketimine derivative, and the unstable intermediate is chemically hydrolyzed to an oxo derivative. 23) Reductive metabolism of ziprasidone, an antipsychotic agent, to dihydroziprasidone by aldehyde oxidase was reported. 120, 121) In this case, the benzisothiazole ring is reductively cleaved via the 2-hydroxythiazole intermediate to an amidine-type metabolite. 121, 122) Aldehyde oxidase showed oxime-reductase activity toward camphor oxime, acetophenone oxime, salicylaldoxime and benzamidoxime, aŠording the corresponding ketimines, and other oxime compounds (except benzamidoxime) are chemically hydrolyzed to oxo compounds. 123) Aldehyde oxidase also functions as a nitroreductase of neonicotinoids, nitroguanidine-type insecticides, such as imidacloprid and thiamethozan. These insecticides are reduced by aldehyde oxidase via two-and sixelectron reduction to nitrosoguanidine and aminoguanidine-type metabolites, respectively, and this reductive metabolism alters the agonistic potency at nicotinic acetylcholine receptors in insects. 124, 125) Both of the molybdenum hydroxylases contribute to the nitroreduction of nitropolycyclic aromatic hydrocarbons in skin, which is one of target organs for environmental contaminants. The skin cytosols of rabbits, guinea pigs, mice and rats all exhibit signiˆcant nitroreductase activity. Aldehyde oxidase participates predominantly in the reduction in skins of hamsters and rabbits, whereas xanthine oxidoreductase participates predominantly in mice and rats, and both ‰avoen-zymes participate in guinea pigs. 60, 61) Aldehyde oxidase in bovine ciliary body also exhibits drug-reductase activity toward nicotinamide N-oxide, nicotinohydroxamic acid, sulindac, 1-nitropyrene and chloramphenicol. 126, 127) Inˆsh, liver aldehyde oxidase also catalyzes the reductive metabolism of 2-nitro‰uorene (sea bream), 1-nitropyrene (carp and sea bream) and fenthion sulfoxide (goldˆsh and sea bream). [43] [44] [45] This cytosolic enzyme seems to play an important role in drug metabolism inˆsh.
Individual Variation of Drug-Metabolizing Ability of
Molybdenum Hydroxylases N 1 -Methylnicotinamide, which is formed from nicotinamide by nicotinamide methyltransferase, is widely distributed in animals, like nicotinamide. N 1 -Methylnicotinamide is neurotoxic, and is detoxiˆed by oxidation to N 1 -methyl-2-pyridone-5-carboxamide and N 1 -methyl-4-pyridone-3-carboxamide (4-PY). The conversion of N 1 -methylnicotinamide to 2-PY and 4-PY has been reported to be catalyzed by aldehyde oxidase. 14, 15) The N 1 -methylnicotinamide oxidase activity shows marked variations among various strains of rats. The activity was highest in Sea:SD, followed by Jcl:SD, and Slc:Wistar W ST rats, while WKA W Sea rats showed the lowest value. The value of Sea:SD rats was about 146-fold higher than that of WKA W Sea rats. 128) We have also found a marked strain diŠerence of liver aldehyde oxidase activity in twelve strains of rats in an assay using benzaldehyde or methotrexate as a substrate. Among the strains tested, the highest activity was observed with Sea:SD rats and the lowest with WKA W Sea rats. The diŠerences between the activities toward benzaldehyde and methotrexate in the two strains of rats were 63.5-and 104-fold, respectively. 50, 53) We suggested that quantitative, but not qualitative, diŠerences of aldehyde oxidase exist among diŠerent strains of rats, since there was little variation of Km values of the enzyme among the strains of rats examined, and Western blot analysis showed that the strains possessed diŠerent quantities of the enzyme. Furthermore, we showed that the strain diŠerences of aldehyde oxidase in rat liver with N 1 -methylnicotinamide as a substrate were well correlated with the activity in vivo 128) (Fig. 7) . Aldehyde oxidase activity is regulated by androgen in mice, which contain four isozymes of the oxidase (AOX1, AOH1, AOH2 and AOH3).
8) The aldehyde oxidase gene cluster in rat chromosome 9 is similar to that in mice, and contains Aox1, Aoh1, Aoh2 and Aoh3. AOX1 and AOH1 are active aldehyde oxidase species in mouse liver, and they have similar substrate speciˆcities, while AOH2 and AOH3 are observed at low levels in skin and olfactory mucosa, respectively. 8) A similar gene cluster exists in humans. 20) Individual variation of xanthine oxidoreductase activity was examined by measurement of the metabolites of caŠeine after a single dose. The amounts of 7-demethylated metabolite formed by CYP1A2 diŠered depending upon race, sex and age, but no diŠerence of the amounts of 8-hydroxylated metabolite generated by xanthine oxidase was observed. 92) Patients with xanthine oxidoreductase deˆciency (xanthinuria) have been classiˆed into two groups; one that lacks xanthine oxidoreductase, and has oxidation ability for allopurinol and pyrazinamide, and another that lacks these activities. As aldehyde oxidase oxidizes these substrates, a combined deˆciency of xanthine oxidoreductase and aldehyde oxidase may exist in the latter group. 129, 130) Johnson et al. 131) also reported combined deˆciency of xanthine oxidoreductase and sulˆte oxidase in xanthinuric patients.
Variation of aldehyde oxidase activity in humans has been discussed in several papers. 21, 24, 132, 133) Marked interindividual variation in methotrexate hydroxylase activity was found in human liver. 134) Zaleplon, a sedative-hypnotic, was reported to be metabolized by aldehyde oxidase and the cytochrome P450 system, and the metabolic pattern was in‰uenced by the level of aldehyde oxidase. 75) We recently examined developmental changes of aldehyde oxidase activity in rats. Little or no activity was observed in fetal or newborn rats, but the activity markedly increased after birth. At 2-3 weeks of age, the activity was about the same as in adult rats (Tayama et al., unpublished data). As is the case in humans, rat studies involving treatment with drugs that are metabolized by aldehyde oxidase require caution. Interindividual variations in aldehyde oxidase activity are of considerable importance for the clinical application of any drug metabolized by the enzyme, including methotrexate, cyclophosphamide, zaleplon and allopurinol.
Drug-Drug Interaction via Aldehyde Oxidase
Various medicinal drugs have inducing or inhibitory eŠects on aldehyde oxidase and xanthine oxidoreductase. In particular, many chemicals inhibit aldehyde oxidase. 135) Aldehyde oxidase-linked activities are markedly inhibited by menadione, isovanillin, chlorpromazine and estradiol, and xanthine oxidoreductase is inhibited by oxypurinol (allopurinol). SKF 525-A and a narcotic analgesic, methadone, show a potent inhibitory eŠect on aldehyde oxidase, and the antihistamines diphenhydramine, pheniramine, doxylamine, orphenadrine, methapyrilene and pyrilamine also inhibit with IC50 values of 100-500 mM.
136) Aldehyde oxidase activity was inhibited after administration of hydralazine (10 mg W kg W day for 7 days) to rabbits, but xanthine oxidoreductase activity was not. 137) Inhibitory eŠects of some medicinal drugs on human liver aldehyde oxidase activity have been reported. 138, 139) For example, aldehyde oxidase activity is suppressed by raloxifene in human liver. 138) Raloxifene inhibited oxidations of phthalazine, vanilin and nicotine iminium ion mediated by aldehyde oxidase. However, raloxifene had only a small eŠect on xanthine oxidoreductase. 138) An inhibititory eŠect of cimetidine on zaleplon metabolism in human liver in vitro was also reported. 140) Bioavailability of zebularine, which is metabolized by aldehyde oxidase, was enhanced by a potent inhibitor, raloxifene, but the eŠect varied markedly in hepatic cytosols from humans, monkeys, dogs, rats, and mice due to species diŠer-ence. 141) In contrast, medicinal drugs that inhibit oxidation reactions catalyzed by aldehyde oxidase do not inhibit the reductive metabolism of ziprasidone to its major metabolite, S-methyldihydroziprasidone, in vitro.
142)
As regards inducing eŠects on both enzyme activities, Dietrich 143) demonstrated that xanthine oxidoreductase activity is increased about twice by xanthine i.p. injection for 6-12 days at 120 mg W kg W day. Johnson et al. 144) showed that phthalazine (50 mg W kg) and its hydroxylated metabolite, 1-hydroxyphthalazine (10 mg W kg), induce both aldehyde oxidase and xanthine oxidoreductase activities in rabbit liver. Recently, we showed that 2,3,7,8-tetrachlorodibenzo-p-dioxin induces xanthine oxidoreductase activity mediated by aryl hydrocarbon receptor. 145) In this case, aldehyde oxidase activity was induced only 1.5-fold by the treatment. Ethacrynic acid, carbon tetrachloride and buthionine sulfoxime also slightly induce xanthine oxidoreductase activity by about 1.5-fold.
146) The enzyme is also induced by bacterial lipopolysaccaride and hypoxia. 147, 148) However, we found that inducers of the cytochrome P450 system, such as phenobarbital, 3-methylcholanthrene and dexamethasone, did not induce these molybdenum hydroxylases in vivo in rats.
Xanthine oxidoreductase in the presence of a suitable electron donor yields superoxide anion, which is associated with edema, ischemia and sepsis syndrome. 31, 149) To prevent these injurious eŠects, attempts have been made toˆnd natural products with an inhibitory eŠect on xanthine oxidoreductase. Chang et al. 150) reported inhibitory eŠects of some ‰avonoids; baicalein was the most potent. Lin et al. 151) also found inhibitory eŠects of ‰avonoids, and noted that the most potent inhibitor is apigenin. In contrast, Rivera et al. 152) reported that aldehyde oxidase and its homologue (AOH1) in mice are induced 2-to 3-fold at the protein levels by dioxin. A similar eŠect was seen in Hepa-1 cells, but the mRNA level in the cells, which lack aryl hydrocarbon receptor or aryl hydrocarbon receptor nuclear translocator, was not enhanced.
When methotrexate is used clinically, the maintenance of an eŠective level is critical. 7-Hydroxymethotrexate is less active, but cytotoxic, and also has other pharmacological eŠects. Clinically, combined usage of methotrexate with cyclosporin resulted in a decrease in the level of 7-hydroxymethotrexate, in blood of patients, and thereby potentiated methotrexate e‹ca-cy. 153) Therefore, external inhibition of methotrexate hydroxylation by aldehyde oxidase could be important in the clinical application of methotrexate. Possible drug-drug interaction through modulation of drugmetabolizing activity based on aldehyde oxidase should always be taken into consideration in the clinical setting.
The purine analogue, allopurinol, has been in clinical use for more than 30 years as an inhibitor of xanthine oxidoreductase in the treatment of hyperuricemia and gout. However, folate compounds and ‰avanoids also inhibit xanthine oxidoreductase.
154) Drug-drug interaction based on inhibition of the enzyme is involved in the interaction of 6-mercaptopurine with allopurinol. 155) It is recommended that the dose of 6-mercaptopurine is reduced by about half when it is coadministered with allopurinol. Pea 156) also reported that when allopurinol is coadministered with azathiopurine and 6-mercaputopurine, their toxic eŠects are potentiated. In this case, it was suggested that azathiopurine exhibits toxicity after conversion to 6-mercaptopurine by reaction with glutathione. 157) Interaction of cyclophosphamide and allopurinol has also been reported. Although allopurinol pretreatment resulted in a longer half-life of cyclophosphamide, urinary metabolites and cyclophosphamide excretion were unchanged. 158) However, Witten et al. 159) reported that although the half-life of cyclophosphamide is not signiˆcantly in‰uenced by allopurinol treatment, that of its metabolite was increased. In contrast, it was demonstrated that allopurinol protects rat hepatocytes against the reactive oxygen-based toxicity of azathiopurine and 6-mercaptopurine.
97)

Estimation of Aldehyde Oxidase Levels In Vivo
The pharmacological action of a drug is closely related to its metabolism. Therefore, variations in aldehyde oxidase activity are of considerable importance for the clinical application of drugs. Variations of aldehyde oxidase in Caucasians and Japanese have been reported. 21, 132) However, no report was available on the prediction of aldehyde oxidase levels in vivo. A method for estimation of the enzyme level in vivo is therefore important to prevent drug overdose.
We examined the in vivo conversion ratio of N 1 -methylnicotinamide to 2-PY and 4-PY as a parameter for the estimation of aldehyde oxidase level in rats. N 1 -Methylnicotinamide and its pyridones (2-PY and 4-PY) are usually detected in the urine of rats. When we measured the ratio of the amount of pyridones to the total amount of N 1 -methylnicotinamide and pyridones (RP value) in the urine of rats, marked intraspecies variations were observed.
The variation in RP value among strains was closely related to the diŠerences of liver aldehyde oxidase activity measured with N 1 -methylnicotinamide as a substrate. RP values after administration of N 1 -methylnicotinamide to diŠerent strains of rats conˆrmed the existence of strain diŠerences of aldehyde oxidase activity in vivo. We also conˆrmed the strain diŠerences of aldehyde oxidase in rat liver with N 1 -methylnicotinamide as a substrate, and showed that the oxidase activity correlated with the activity in vivo (Fig. 7) . Thus, the quantitative variation of the enzyme in liver appears to be the cause of strain diŠerences of N 1 -methylnicotinamide metabolism in rats in vivo. Therefore, we had demonstrated that measurement of RP values in urine is a useful method to predict the in vivo level of aldehyde oxidase in animals and humans. 128) Reiter et al. 129) suggested a deˆciency of aldehyde oxidase in humans by using a method similar to ours, that involved measuring the amounts of pyridones of N 1 -methylnicotinamide in human urine. However, whether there is a genetic deˆciency of aldehyde oxidase in humans is unclear. Furthermore, it was shown by us that the degree of 7-hydroxylation of methotrexate in rats in vivo closely re‰ects strain diŠerences of aldehyde oxidase-based methotrexate 7-hydroxylase activity in the liver (Moriyasu et al., unpublished data).
Recently, chimeric mice, which contain human liver cells, have been produced for use in preclinical studies. We attempted to estimate in vivo aldehyde oxidase activity in these chimeric mice. It was established that human-type metabolism of N 1 -methylnicotinamide by aldehyde oxidase occurred in these mice in vivo, and that the aldehyde oxidase in these mice is a typical human-type aldehyde oxidase, but not mouse-type aldehyde oxidase.
160)
Conclusion
Recently, increased attention has been paid to drug metabolism mediated by aldehyde oxidase and xanthine oxidoreductase, and to the possibility of drug-drug interaction associated with interindividual variation of these enzyme activities. It appears that variation of these enzyme activities can markedly in‰uence the disposition of medicines that are metabolized by them, and can be clinically signiˆcant. Furthermore, as the activity of aldehyde oxidase in humans is very high compared with those in experimental animals, the results of drug disposition studies in rats and mice can not necessarily be extrapolated to humans. It is important to consider potential drug-drug interactions mediated by molybdenum hydroxylases, as well as the well-known interactions mediated by cytochrome P450. 
